
|Articles|March 22, 2004
Antipsychotics, obesity, diabetes: Breaking the lock
Second-generation antipsychotics (SGAs), while clinically better than their earlier counterparts, have been associated with dramatic weight gain, diabetes and an atherogenic lipid profile.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Expands Approval of Flibanserin for Postmenopausal Women’s Sexual Health
2
Q&A: How Complex US Drug Market Impedes MFN Pricing Policy
3
Variation in Insulin Pump Options Creates Opportunity for Pharmacist Counseling | ASHP Midyear 2025
4
OTC Products: Cold and Flu
5



























































































































